Physician profile
Janak H Bhavsar
NPI 1013995406
$236,632.63
in general payments reported to CMS, 2019-2025
42 companies · $221K in 2025
The $221K reported for 2025 was more than what 99% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,276 · 2020: $824 · 2021: $976 · 2022: $2,375 · 2023: $1,603 · 2024: $1,412 · 2025: $221K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $220K · Food and Beverage: $3,290 · Consulting Fee: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $220,391.70 |
| Food and Beverage | $3,289.70 |
| Consulting Fee | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $220,391.70 | 2025 | |
| Medtronic Vascular, INC. | $6,990.88 | 2019-2020 | |
| Penumbra, INC. | $1,554.76 | 2022-2025 | Indigo System, Penumbra System |
| Abiomed | $945.55 | 2019-2025 | Impella |
| Cardiovascular Systems INC. | $789.58 | 2019-2023 | Diamondback Coronary, Diamondback Peripheral |
| Cvrx, INC. | $663.53 | 2019-2025 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $656.71 | 2019-2025 | |
| Inari Medical, INC. | $572.88 | 2020-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Janssen Pharmaceuticals, INC | $465.04 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $454.76 | 2021-2025 | Verquvo, Capvaxive |
| Abbott Laboratories | $405.64 | 2019-2025 | Amplatzer Amulet, Diamondback Coronary, Jeti Peripheral Catheter |
| Medtronic, INC. | $282.98 | 2021-2025 | Turbohawk, Linq II, Hawkone |
| Pfizer INC. | $277.31 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $252.07 | 2020-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $207.22 | 2022-2024 | Jardiance |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $194.63 | 2019-2025 | Repatha, Repatha |
| Biotronik INC. | $171.15 | 2020-2022 | |
| Astrazeneca Pharmaceuticals Lp | $170.18 | 2019-2022 | |
| Boston Scientific Corporation | $149.23 | 2019-2025 | Avvigo Guidance System, Eluvia, Ranger |
| Kestra Medical Technology Services, INC. | $99.87 | 2022-2024 | Assure Wcd |
| Cook Medical LLC | $97.53 | 2019-2025 | Rosen |
| E.R. Squibb & Sons, L.L.C. | $89.52 | 2023-2025 | Eliquis, Camzyos |
| Roche Diagnostics Corporation | $88.40 | 2019 | |
| Philips North America LLC | $68.70 | 2022-2024 | (Az7) Lasers, (Ck4) Mcot |
| Esperion Therapeutics, INC. | $48.37 | 2020-2024 | Nexletol |
| W. L. Gore & Associates, INC. | $48.29 | 2024 | Gore Viabahn Endoprosthesis With Heparin |
| Bardy Diagnostics, INC. | $48.00 | 2019-2021 | |
| Acist Medical Systems, INC. | $44.79 | 2019-2020 | |
| Angiodynamics, INC. | $42.59 | 2022 | |
| Biosense Webster, INC. | $41.01 | 2024 | |
| Alnylam Pharmaceuticals INC. | $40.35 | 2025 | Amvuttra |
| Siemens Medical Solutions USA, INC. | $39.92 | 2019 | |
| Amarin Pharma, INC. | $39.40 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $39.11 | 2019 | |
| Teleflex LLC | $34.33 | 2019-2025 | D-Stat |
| Ekos Corporation | $33.66 | 2019 | |
| Irhythm Technologies, INC. | $24.10 | 2024 | Zio Monitor, Zio Xt Patch |
| Cardiva Medical, INC. | $20.93 | 2022 | |
| Impulse Dynamics (USA) INC. | $20.30 | 2022 | |
| Bard Peripheral Vascular, INC. | $14.71 | 2020 | |
| Livanova USA, INC. | $12.95 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$406,703.92 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janak Bhavsar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.